MedTrace Logo

Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study.

NCT02629536 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2015-12-14

No results posted yet for this study

Summary

Migraine affects 15% of Western Australians and is a leading cause of suffering and disability in our community (1,2). Research suggests that inflammation of the brain's coverings (meninges) by nerve cell inflammation and the release of 'free radicals', is a cause of migraine. N-acetylcysteine, Vitamin E and Vitamin C are powerful anti-oxidants (free-radical scavengers) that reduce brain inflammation and nerve activity. It is therefore possible these anti-oxidants could reduce the number and severity of migraines. We will study 90 subjects to see if a combination of N-acetylcysteine 600 mg, Vitamin E 250 IU and vitamin C 500 mg (NEC) taken twice daily for 3 months, will reduce migraine attacks. This safe vitamin-based therapy has never been studied and if effective, will play an important role in migraine prevention.

Conditions

  • Migraine, Headaches

Interventions

DRUG

N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet

N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet

Sponsors & Collaborators

  • University of Notre Dame Australia

    lead OTHER

Principal Investigators

  • Eric J Visser, MBBS · University of Notre Dame Australia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-03-31
Completion
2017-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02629536 on ClinicalTrials.gov